Newswire (Published: Thursday, March 19, 2020, Received: Thursday, March 19, 2020, 3:39:15 PM CDT)

Word Count: 563

2020 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Defense & Aerospace Daily -- Fresh data on Veterans Health are presented in a new report. According to news reporting out of New York City, New York, by NewsRx editors, research stated, “Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naive metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone).”

Financial supporters for this research include Pfizer Inc. (New York, NY, USA), Astellas Pharma, Inc. (Northbrook, IL, USA), STATinMED.

Our news journalists obtained a quote from the research from Pfizer, “We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. We identified 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p< 0.0001) and PC-related outpatient visits (0.86 vs 1.03; p< 0.0001), with corresponding lower all-cause ($2588 vs $3115; p< 0.0001) and PC-related ($1356 vs $1775; p< 0.0001) PPPM outpatient costs compared with the abiraterone cohort. All-cause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p< 0.0001) were significantly lower in the enzalutamide cohort compared with the abiraterone cohort. Enzalutamide-treated men with chemotherapy-naive mCRPC had significantly lower resource utilization and healthcare costs compared with abiraterone-treated men.”

According to the news editors, the research concluded: “Plain Language Summary Plain language summary available for this article.”

For more information on this research see: Economic Outcomes In Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in Therapy, 2020;():. Advances in Therapy can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer -; Advances in Therapy -

Our news journalists report that additional information may be obtained by contacting K. Ramaswamy, Pfizer, New York, NY 10017, United States. Additional authors for this research include J. Mardekian, S. Lechpammer, A. Huang, L. Wang, N.M. Schultz, R. Sandin, O. Baser and D.J. George.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


Pfizer Inc.
Astellas Pharma Inc.
Astellas Pharma Inc.
Veterans Health Administration


Aerospace and Defense


North America
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies